Publications by authors named "Rachel A Toroni"

Claim this Profile
G
Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer.
Yesim Gökmen-Polar, Chirayu P Goswami, Rachel A Toroni, Kerry L Sanders, Rutika Mehta

J Cancer· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.
Jamie N Anastas, Rima M Kulikauskas, Tigist Tamir, Helen Rizos, Georgina V Long, Rachel A Toroni

J Clin Invest· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protein kinase PKN1 represses Wnt/β-catenin signaling in human melanoma cells.
Richard G James, Katherine A Bosch, Rima M Kulikauskas, Peitzu T Yang, Nick C Robin, Rachel A Toroni

J Biol Chem· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models.
Yesim Gökmen-Polar, Yi Liu, Rachel A Toroni, Kerry L Sanders, Rutika Mehta

Breast Cancer Res Treat· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
WLS inhibits melanoma cell proliferation through the β-catenin signalling pathway and induces spontaneous metastasis.
Pei-Tzu Yang, Jamie N Anastas, Rachel A Toroni, Michi M Shinohara, Jamie M Goodson

EMBO Mol Med· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma.
Travis L Biechele, Rima M Kulikauskas, Rachel A Toroni, Olivia M Lucero, Reyna D Swift

Sci Signal· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.
Yesim Gökmen-Polar, Rachel A Toroni, Barbara A Hocevar, Sunil Badve, Qianqian Zhao

Breast Cancer Res Treat· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis